FDA Approves Once-Weekly Bydureon BCise (exenatide) for Patients with Type-2 Diabetes

23 October 2017 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon ® BCise™ (exenatide extended-release) injectable suspension, a new formulation of Bydureon (exenatide extended-release) injectable...

Source: Drugs.com - New Drug Approvals - October 23, 2017 Category: Drugs & Pharmacology Source Type: news